Stockreport

BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomy...

BridgeBio Pharma, Inc.  (BBIO) 
Last bridgebio pharma, inc. earnings: 3/2 08:29 am Check Earnings Report
PDF - Marketing Authorization Application accepted by the European Medicines Agency (EMA) with additional global regulatory submissions planned - In ATTRibute-CM, acorami [Read more]